The flow diagram shows the progression of subjects from screening to completion of the study.
Total unadjusted Unified Parkinson's Disease Rating Scale (UPDRS) score by visit for each treatment group. Error bars indicate ± 1 SE.
. A Controlled Trial of Rasagiline in Early Parkinson DiseaseThe TEMPO Study. Arch Neurol. 2002;59(12):1937-1943. doi:10.1001/archneur.59.12.1937
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
Monotherapy with rasagiline mesylate may be useful in early Parkinson disease (PD).
To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitor rasagiline.
Multicenter, 26-week, parallel-group, randomized, double-blind, placebo-controlled clinical trial.
Academically based movement disorders clinics.
Patients with early PD not requiring dopaminergic therapy (n = 404).
Research participants were randomized to rasagiline mesylate at dosages of 1 mg or 2 mg per day or matching placebo. A 1-week escalation period was followed by a 25-week maintenance period.
Main Outcome Measure
The primary prespecified measure of efficacy was the change in the total Unified Parkinson's Disease Rating Scale score between baseline and 26 weeks of treatment, comparing each active treatment group with the placebo group.
Monotherapy with rasagiline was effective in this 26-week study. The adjusted effect size for the total Unified Parkinson's Disease Rating Scale was −4.20 units comparing 1 mg of rasagiline and placebo (95% confidence interval, −5.66 to −2.73 units; P<.001) and −3.56 units comparing a 2-mg dosage and placebo (95% confidence interval, −5.04 to −2.08 units; P<.001). There were no meaningful differences in the frequency of adverse events or premature withdrawals among the treatment groups.
Rasagiline is effective as monotherapy for patients with early PD. The 2 dosages in this trial were both effective relative to placebo. Further study is warranted to evaluate the longer-term effects of rasagiline in PD.
RASAGILINE (N-propargyl-1(R)-aminoindan; TVP-1012) mesylate is a selective irreversible inhibitor of monoamine oxidase type B (MAO-B).1 Dosages of 1 mg/d cause almost total inhibition of platelet MAO-B activity in humans.2 In experimental states of dopamine hypofunction, rasagiline, without concomitant levodopa, restored normal locomotor and cognitive function.3 In primates, rasagiline has been shown to increase striatal extracellular dopamine concentrations.4 Its major metabolite, aminoindan, has been shown to be active in rodent models relevant to Parkinson disease (PD).3
In a 10-week, randomized, placebo-controlled trial of rasagiline in patients with early, untreated PD,5 dosages of up to 4 mg/d were well tolerated. There were no occurrences of hypertension, bradycardia, or other cardiovascular adverse experiences. Based on these preliminary data, we conducted a randomized, multicenter, placebo-controlled, double-blind clinical trial over 6 months to determine the efficacy, safety, and tolerability of rasagiline on parkinsonian characteristics in untreated patients with early PD who had not developed sufficient disability to require dopaminergic therapy.
This multicenter study, organized by the Parkinson Study Group and sponsored by Teva Pharmaceutical Industries, Ltd (Netanya, Israel) and Teva Neuroscience, LLC (North Wales, Pa), was reviewed and approved by the institutional review board at each of the participating centers.
Between November 1997 and June 1999, 404 eligible patients were enrolled in the trial at 32 sites in the United States and Canada. Eligible patients included those older than 35 years who had the presence of at least 2 of the cardinal signs of PD and whose disease severity was not greater than Hoehn and Yahr stage III.6 Subjects were excluded if they had (1) atypical or secondary parkinsonism, (2) unstable medical problems, including congestive heart failure of New York Heart Association class II or greater, (3) psychiatric problems that compromised the ability of the subject to give informed consent, (4) a Mini-Mental State Examination7 score of 23 or less, or (5) clinically significant depression. Subjects could be treated with anticholinergic medications, but other antiparkinsonian medications, including levodopa, dopamine agonists, selegiline, or amantadine, were not permitted. Antidepressants (with the exception of amitriptyline, paroxetine, sertraline, fluvoxamine, or trazodone) and sympathomimetics were not permitted.
A randomized, double-blind, placebo-controlled, parallel-group design was employed. Eligible and consenting patients were randomly assigned at the baseline evaluation to 1 of 3 groups: rasagiline mesylate, 1 mg/d; rasagiline mesylate, 2 mg/d; or matching placebo. All patients, investigators, and coordinating staff were kept unaware of treatment assignments.
Patients received 1 mg or 2 mg of rasagiline or matching placebo (Teva Pharmaceutical Industries, Ltd) once daily. In a pilot study, these dosages were well tolerated, and there was preliminary evidence for efficacy at both dosages.5 Experimental treatment began with a 1-week titration period during which all subjects on active treatment received 1 mg/d of rasagiline. After 1 week, subjects assigned to 2 mg/d of rasagiline took the maintenance dosage for the remaining 25-week period. Subjects assigned to the 1 mg/d group continued to take that dosage for the remainder of the trial. Addition of or change in anticholinergic therapy was not allowed during the study.
The prespecified primary measure of efficacy in the trial was the change in total Unified Parkinson's Disease Rating Scale (UPDRS) score between baseline and the week 26 visit. Research participants who left the study prematurely or who were judged to require additional dopaminergic therapy before the week 26 visit had their last UPDRS scores carried forward.
Secondary measures of efficacy included changes in the mental, activities of daily living (ADL), and motor subscales of the UPDRS, as well as symptom-based subscores (tremor, rigidity, bradykinesia, and postural instability/gait disorder).8 Other secondary outcome variables included changes in the Hoehn and Yahr stage, the Schwab-England ADL scale, Beck Depression Inventory9 score, timed motor tests,10 and the Parkinson's Disease Quality of Life (PDQUALIF) scale.11 All subjects who experienced a worsening of less than 3 units in their total UPDRS score from baseline to 26 weeks were classified as responders. In making the determination of the need for levodopa, the investigator was asked to consider the impact of PD symptoms on the ability of the research participant to remain employed, manage finances, carry out domestic responsibilities, and perform ADL.12 Measures of safety included frequency and severity of reported adverse effects.
A statistical analysis plan was developed prior to unblinding. The primary statistical analyses were performed according to the intention-to-treat principle.13 For the analyses of the efficacy measures, if a subject was missing a response at a particular visit, the last available observation was carried forward and imputed for that visit. An overall significance level of 5% was used for formal significance testing and interval estimation.
The primary prespecified analysis of efficacy used analysis of covariance to compare the mean changes from baseline to last visit in each active treatment group with changes in the placebo group. All enrolled subjects with postrandomization data were included in the analysis. Baseline UPDRS score and rating investigator were included in the model as covariates. In the prespecified analysis plan, the treatment × investigator interaction term was to be included in the model if it was statistically significant at a level of P<.05. The Hochberg step-up Bonferroni method was used to control the overall type I error rate in the primary comparison.14 A primary comparison would be declared significant if it achieved P<.025 or if both comparisons (1-mg and 2-mg dosages vs placebo) satisfied P<.05.
Secondary outcome measures were analyzed in the same way as the primary response measure, except for time to levodopa therapy, which was analyzed using life-table techniques. Logistic regression was used to compare the proportion of responders in the 3 treatment groups. The total PDQUALIF score was calculated as the sum of the 32 individual items on the questionnaire.11 Analyses of safety measures were descriptive. Frequencies of adverse experiences and abnormal laboratory test results, vital signs, and electrocardiogram results were analyzed, with imbalances among treatment groups flagged at a nominal 5% level as judged by χ2 tests.
Using data from prior studies conducted by the Parkinson Study Group, the pooled SD of the primary outcome measure was projected to be 7.4 units. Using the Hochberg step-up Bonferroni method, a sample size of 120 per group (total, 360 subjects) was estimated to give power between 81% and 93% to detect a significant effect of either or both dosages of rasagiline, when the true effect of 2 mg of rasagiline corresponds to a 3-unit improvement relative to placebo and the effect of 1 mg of rasagiline is between 0 and 3 units.
Of the 473 subjects screened as potential study participants, 69 were found to be ineligible at screening. The most common specific reason for nonparticipation was failure to meet inclusion criteria (Figure 1). The 3 treatment groups were similar at baseline with regard to demographic variables. The baseline UPDRS ADL and mental scores were slightly higher (more impaired) in the 2-mg rasagiline group than in the other 2 groups. There were no significant differences between the groups with regard to total UPDRS or motor subscale scores at baseline (Table 1).
The 26-week total UPDRS (last available observation carried forward) unadjusted mean (SD) scores were 24.8 (12.3), 26.6 (11.8), and 28.4 (14.3) for the 1-mg, 2-mg, and placebo groups, respectively. The unadjusted changes from baseline were 0.1 (6.8), 0.7 (5.8), and 3.9 (7.5), respectively. Figure 2 shows mean values and SEs of total UPDRS score by visit for all patients with data for that visit. Results restricted to the 328 patients who completed 6 months without additional therapy were similar (data not shown).
Adjusted total UPDRS score mean changes from baseline were calculated from the model that included baseline UPDRS scores and center-treatment interaction (Table 2). Both active treatment groups showed benefits relative to the placebo group (P<.001 for each comparison). The responders' analysis of participants who experienced a less than 3-unit change in total UPDRS score also showed the effects of each active treatment (placebo, 49%; 1 mg, 66%; and 2 mg, 67%; P = .004 and P = .001 for the 1-mg and 2-mg groups, respectively, compared with the placebo group).
Of 138 subjects in the placebo group, 23 (16.7%) reached the secondary end point of needing levodopa therapy, compared with 15 (11.2%) of 134 subjects and 22 (16.7%) of 132 subjects in the 1-mg and 2-mg treatment groups, respectively. Kaplan-Meier analysis showed no statistically significant differences in the time to need for additional therapy among the 3 groups.
Both active treatment groups showed significant improvements in PDQUALIF scores compared with the placebo group. Exploratory analysis suggested that the benefit occurred primarily in the subscale measuring self-image/sexuality, with borderline effects on the social role subscale. Significant benefits were also noted in responses to the single question comparing present PD symptoms with those 3 months previously.
Adverse events were no more frequent in the active treatment groups than in the placebo group. The most commonly observed adverse experiences were infection (16%) and headache (12%). No other adverse event occurred with a frequency of more than 10%. All adverse events occurring with a frequency of more than 5% are shown in Table 3. There were no statistically significant differences in the rates of early termination between the treatment groups and the placebo group. The percentages of subjects with at least 95% compliance in each group were comparable (placebo, 92.8%; 1 mg, 91.8%; and 2 mg, 89.4%).
Twenty serious adverse events (defined as hospitalizations or new malignancies) occurred during the study. Four occurred in the placebo group (2 hospitalizations for elective operations, 1 for dizziness, and 1 for chest pain); 6 occurred in the 1 mg/d of rasagiline group (1 hospitalization for diverticulosis, 1 for surgical removal of benign ovarian masses, 1 for surgical repair of an aortic aneurysm, 1 for cardiac bypass surgery, 1 for atrial fibrillation, and 1 for angina); and 10 occurred in the 2 mg/d of rasagiline group (1 hospitalization for diverticulitis, 2 for chest pain, 1 for constipation, 1 for abdominal pain, and 3 participants with newly diagnosed malignancies [malignant melanoma, prostate carcinoma, and squamous cell carcinoma of the skin]). One subject in the 2 mg/d group experienced 2 serious adverse events (hospitalization for depression and delirium during that hospitalization).
There were no differences in laboratory test results, electrocardiogram abnormalities, standing or supine pulse, or standing blood pressure among the 3 groups. There was a small (4.04 mm Hg) but significant (P = .02) increase in supine systolic blood pressure in the 2-mg group relative to the placebo group, but not in the 1-mg group (2.37 mm Hg; P = .16). There were no differences in supine diastolic blood pressure or standing systolic or diastolic blood pressure.
This randomized, placebo-controlled clinical trial demonstrated that rasagiline at dosages of 1 mg and 2 mg per day results in better overall UPDRS performance compared with placebo over a 26-week period in patients with early PD. Significant differences between active treatment and placebo were also found in the motor and ADL subscales of the UPDRS and in the PDQUALIF scale. In addition, a higher proportion of patients in the active treatment groups responded to therapy, as judged by their change in total UPDRS score compared with the placebo group. There were no advantages in efficacy for 2 mg/d of rasagiline compared with the 1 mg/d dosage.
The magnitude of the symptomatic benefit of rasagiline seen in this study was comparable to that for selegiline over a comparable 6-month period in the DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) study15,16 and studies of the MAO-B inhibitor lazabemide.17,18 In DATATOP, subjects treated with selegiline experienced a difference in total UPDRS scores after 3 months of approximately 3 units. When followed for up to 24 months, the difference between those receiving placebo and those receiving selegiline approached 7 units. A difference of approximately 2 units in total UPDRS score was seen after 6 months between lazabemide and placebo.19
Studies of both lazabemide and selegiline have shown significant differences in the proportion of subjects who reached the end point of need for dopaminergic therapy. By contrast, no difference was seen in the current study, despite a comparable symptomatic effect as measured by UPDRS. (Explanations of the lack of difference in the need for levodopa in this trial are clearly speculative.) In contrast to the other trials, time to need for levodopa was not the primary end point of this trial, and it was not powered to detect a difference in this secondary end point over a 6-month period. It is possible that changes in investigator practices over time or the knowledge that all subjects would receive active treatment after 6 months may have influenced the decision to add or delay dopaminergic therapy.
The symptomatic effect of rasagiline in this study is more modest than the effects observed with dopamine agonists as monotherapy for PD.20- 22 However, the difference between these effects is relatively small (less than 4 UPDRS units), and a direct comparison would be needed to determine if dopamine agonists do, indeed, provide superior symptomatic relief. The incidence of adverse experiences, particularly somnolence, peripheral edema, hallucinations, nausea, and constipation, is higher with dopamine agonists than was observed in this trial. As a result, initial therapy with rasagiline rather than a dopamine agonist might be a way to provide effective therapy for patients with mild disease while minimizing some adverse effects.
Adverse experiences have been generally mild and infrequent in trials involving MAO-B inhibitors as monotherapy in early PD. This is true despite concern about cardiovascular responses caused by nonspecific MAO inhibition.18 In this trial, adverse events did not occur with greater frequency in subjects receiving rasagiline than in those receiving placebo. There were no differences in vital signs, with the exception of supine systolic blood pressure, which was slightly higher in the 2 mg/d of rasagiline group than in either the 1-mg or placebo group. Adverse experiences that might be associated with vital sign changes such as hypertension or orthostatic hypotension were reported infrequently in all 3 groups.
The most likely mechanism of action of rasagiline is through inhibition of MAO-B leading to slower catabolism of endogenous dopamine. However, other mechanisms are also possible. In addition to the effect of MAO-B on dopamine catabolism, rasagiline possesses an aminoindan metabolite with antiparkinsonian properties.3 Rasagiline has been shown to protect neurons against a range of experimentally induced neuronal injuries23- 26 in animal models and exert an antiapoptotic effect in cell culture.27 Therefore, another possible mechanism of action of rasagiline is through slowing the rate of loss of dopaminergic neurons. A longer-duration study with a different design would be needed to examine the potential disease-modifying effects of rasagiline.
This 26-week controlled study indicates that rasagiline is an effective therapy for patients with early PD and may be a reasonable treatment option for these patients. Further studies over longer periods of time are needed to determine the effect of rasagiline on patients receiving treatment with levodopa and dopamine agonists and on the potential of this selective MAO-B inhibitor to modify the progression of PD.
Accepted for publication August 29, 2002.
Author contributions: Study concept and design (Drs Shoulson, Fahn, Kieburtz, Stern Oakes, Siderowf, Blindauer, Oren, Levy, and Ladkani, Ms Plumb, and Mr Eyal); acquisition of data (Drs Lew, Hurtig, Lloyd, Hauser, Golbe, Wojcieszek, Feigin, Ondo, Calabrese, Atchison, Marshall, Miyasaki, T. Mendis, N. Mendis, Hubble, Pahwa, Molho, Shulman, Rajput, Stacy, Bertoni, Tuite, K. Shannon, Tanner, Marek, Aminoff, Dowling, Kang, Sethi, Martin, Adler, LeWitt, Schear, Gordon, Feldman, and Nutt, Mss Day, Shinaman, Brocht, Gauger, Belden, Klimek, B. Shannon, Hunter, Allen, Berry, Gardiner, Del Rizzo, Gray, Betcher, Brown, Ewanishin, Williamson, Peterson, Ebbitt, Jaglin, Stavris, DiMinno, Richman, King, McInnes, DeAngelis, Winnick, Thomas, Conn, Connolly, Daigneault, Oliva, and Josephson, and Messrs Chadwick and Houck); analysis and interpretation of data (Drs Siderowf, Shoulson, Oakes, Fahn, Kieburtz, Blindauer, Stern, Schwid, Lang, White, and Cox and Mss Eberly, Bausch, Irvine, and Plumb); drafting of the manuscript (Drs Siderowf, Shoulson, Oakes, Kieburtz, Fahn, Blindauer, and Stern); critical revision of the manuscript for important intellectual content (Drs Lew, Hurtig, Lloyd, Hauser, Golbe, Wojcieszek, Feigin, Ondo, Calabrese, Atchison, Marshall, Miyasaki, T. Mendis, N. Mendis, Hubble, Pahwa, Molho, Shulman, Rajput, Stacy, Bertoni, Tuite, K. Shannon, Tanner, Marek, Aminoff, Dowling, Kang, Sethi, Martin, Adler, LeWitt, Schear, Gordon, Feldman, Lang, White, Schwid, Cox, Nutt, Ladkani, Oren, and Levy, Mss Day, Shinaman, Brocht, Gauger, Belden, Klimek, B. Shannon, Hunter, Allen, Berry, Gardiner, Del Rizzo, Gray, Betcher, Brown, Ewanishin, Williamson, Peterson, Ebbitt, Jaglin, Stavris, DiMinno, Richman, King, McInnes, DeAngelis, Winnick, Thomas, Conn, Connolly, Daigneault, Oliva, Josephson, Irvine, Eberly, and Bausch, and Messrs Chadwick, Houck, and Eyal); statistical expertise (Drs Oakes and Cox, Mss Eberly, Bausch, and Irvine, and Mr Eyal); obtained funding (Drs Shoulson and Kieburtz and Mss Day and Shinaman); administrative, technical, and material support (Drs Lew, Hurtig, Lloyd, Hauser, Golbe, Wojcieszek, Feigin, Ondo, Calabrese, Atchison, Marshall, Miyasaki, T. Mendis, N. Mendis, Hubble, Pahwa, Molho, Shulman, Rajput, Stacy, Bertoni, Tuite, K. Shannon, Tanner, Marek, Aminoff, Dowling, Kang, Sethi, Martin, Adler, LeWitt, Schear, Gordon, Feldman, Lang, White, Nutt, Ladkani, Oren, and Levy, Mss Brocht, Gauger, Belden, Klimek, B. Shannon, Hunter, Allen, Berry, Gardiner, Del Rizzo, Gray, Betcher, Brown, Ewanishin, Williamson, Peterson, Ebbitt, Jaglin, Stavris, DiMinno, Richman, King, McInnes, DeAngelis, Winnick, Thomas, Conn, Connolly, Daigneault, Oliva, and Josephson, and Messrs Chadwick and Houck); study supervision (Drs Shoulson, Siderowf, Fahn, Kieburtz, Blindauer, Schwid, and Stern and Ms Plumb).
The following members of the Parkinson Study Group participated in the TEMPO (Rasagiline Mesylate [TVP-1012] in Early Monotherapy for Parkinson's Disease Outpatients) study and were authors of this report.
University of Pennsylvania, Philadelphia: Andrew Siderowf, MD (medical monitor), Matthew Stern, MD; University of Rochester, Rochester, NY: Ira Shoulson, MD (principal investigator), Karl Kieburtz, MD (director, Clinical Trials Coordination Center), David Oakes, PhD (chief biostatistician), Denni Day, RN, MPH (research administrator), Aileen Shinaman, JD (executive director), Sandra Plumb, BS (senior project coordinator); Columbia-Presbyterian Medical Center, New York, NY: Stanley Fahn, MD (co–principal investigator); Medical College of Wisconsin, Milwaukee: Karen Blindauer, MD.
Participating Investigators and Coordinators
University of Southern California, Los Angeles: Mark Lew, MD; University of Pennsylvania: Howard Hurtig, MD, Mary Lloyd, RN, PhD; University of South Florida, Tampa: Robert Hauser, MD, Lisa Gauger, BA; University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick: Lawrence Golbe, MD; Indiana University School of Medicine, Indianapolis: Joanne Wojcieszek, MD, Joann Belden, RN; North Shore University Hospital, Manhassett, NY: Andrew Feigin, MD, Mary Lou Klimek, RN, Barbara Shannon, RN; Baylor College of Medicine, Houston, Tex: William Ondo, MD, Christine Hunter, RN; Medical College of Virginia, Richmond: Vincent Calabrese, MD; University of Alabama at Birmingham: Paul Atchison, MD, Cathy Allen, RN, BSN; University of Rochester: Frederick Marshall, MD, Debra Berry, MSN, NP, Irenita Gardiner, RN; Toronto Western Hospital, University Health Network, Toronto, Ontario: Janis Miyasaki, MD, FRCPC, Luisa Del Rizzo, RN; Parkinson's Clinic, Ottawa, Ontario: Tilak Mendis, MD, Neila Mendis, MD, Peggy Gray, RN, BSCN; Ohio State University, Columbus: Jean Hubble, MD, Karen Betcher, RN; University of Kansas Medical Center, Kansas City: Rajesh Pahwa, MD; Albany Medical College, Albany, NY: Eric Molho, MD, Diane Brown, RN; University of Miami, Miami, Fla: Lisa Shulman, MD; Saskatoon District Health Board, Royal University Hospital, Saskatoon, Saskatchewan: Ali Rajput, MD, Marianne Ewanishin, RN; Barrow Neurological Institute, Phoenix, Ariz: Mark Stacy, MD, Kelli Williamson, RN; Creighton University, Omaha, Neb: John Bertoni, MD, Carolyn Peterson, RN; Fairview-University Medical Center, University of Minnesota, Minneapolis: Paul Tuite, MD, Brenda Ebbitt, RN, CS; Rush-Presbyterian/St Luke's Medical Center, Chicago, Ill: Kathleen Shannon, MD, Jean Jaglin, RN, CCRC; the Parkinson's Institute, Sunnyvale, Calif: Caroline Tanner, MD; Yale University School of Medicine, New Haven, Conn: Kenneth Marek, MD, Karen Stavris, RN, MSN; University of California, San Francisco: Michael J. Aminoff, MD, Mariann DiMinno, BS, MA, Glenna Dowling, RN, PhD; University of Chicago, Chicago: Un Jung Kang, MD, Judy Richman, RN, BSN; Medical College of Georgia, Augusta: Kapil Sethi, MD; University of Alberta, Edmonton: Wayne Martin, MD, Pamela King, RN, Germaine McInnes, RN; Mayo Clinic Scottsdale, Scottsdale, Ariz: Charles Adler, MD, PhD; Clinical Neuroscience Center, Southfield, Mich: Peter LeWitt, MD, Maryan DeAngelis, RN; Mount Sinai Medical Center, New York: Myrna Schear, MD; Long Island Jewish Medical Center, New Hyde Park, NY: Mark Forrest Gordon, MD, Roberta Winnick, RN; Boston University School of Medicine, Boston, Mass: Robert Feldman, MD, Cathi-Ann Thomas, RN, MS.
Biostatistics and Coordination Centers Staff
University of Rochester: Kelly Conn, BS, Alicia Brocht, BA, Chris Chadwick, BA, Jeannette Connolly, BA, Susan Daigneault, Shirley Eberly, MS, Janice Bausch, BS, Lee Josephson, BA, Rosemary Oliva, BA, Steven Schwid, MD (associate director, Clinical Trials Coordination Center).
Safety Monitoring Committee
University of Toronto: Anthony Lang, MD (chair); University of Rochester: Christopher Cox, PhD, Carrie Irvine, BS; Oregon Health Sciences University, Portland: John Nutt, MD; University of Connecticut, Farmington: William White, MD.
Teva Pharmaceutical Industries, Ltd: Sheila Oren, MD, Ruth Levy, PhD, Eli Eyal, MSc, David Ladkani, PhD; Teva Neuroscience LLC: Wayne Houck, MBA.
Corresponding author and reprints: Andrew Siderowf, MD, University of Pennsylvania, 330 S Ninth St, Philadelphia, PA 19107 (e-mail: email@example.com).